What it is & primary uses
N-acetylcysteine is a precursor to glutathione and a medication used in specific clinical contexts.
Main benefits
- Supports glutathione synthesis
- May help thin respiratory mucus
Studied protocols
Research doses are grouped by outcome. They describe study designs—not a personal prescription.
600–1,200 mg/day
- Study duration
- At least 3 months in prevention studies
- Interpretation
- Evidence is condition-specific; ≥1,200 mg/day was more relevant in documented airway obstruction.
04Food sources & equivalents＋
Can food provide a studied amount?
N-acetylcysteine is an acetylated cysteine derivative used as a supplement and medication, not a standard food nutrient.
Dietary cysteine and methionine, not a measured NAC dose
- How this was estimated
- Dietary cysteine cannot be converted directly into a milligram NAC exposure.
- Important limitation
- Foods can support normal amino-acid nutrition, but they do not reproduce oral or medical NAC dosing. Clinical NAC uses are distinct from dietary intake.
Food equivalents compare ingredient mass using published composition values. They do not prove equal absorption, formulation, physiological effect, safety or personal need.
Source: NIH ODS: N-acetylcysteine overview ↗05How to take it for absorption & tolerance＋
With or without food
NAC is absorbed orally but has low and variable bioavailability; food instructions vary by product and clinical use.
- Practical approach
- Take consistently, with food if nausea occurs, and separate only when the product or clinician specifically directs it.
- Watch for
- Supplement use is not interchangeable with medically supervised NAC treatment.
Meal guidance reflects human pharmacokinetic, clinical, official-label or evidence-review sources where available. A food pairing can change absorption or tolerability, but does not make a supplement necessary, effective or safe for every person.
Source: Clinical pharmacology of N-acetylcysteine ↗06Supplement interaction check＋
An unlisted pair means no established pair-specific interaction was identified in this review—not proof that every dose, product or person is safe.
This is not proof that every dose, product or user context is safe. Medication and condition checks still apply.
07Research notes＋
Moderate as a mucolytic adjunct in chronic bronchitis/COPD populations. General antioxidant, detox and exercise claims are not established by comparable evidence.
Supplement use is distinct from medically supervised NAC treatment.
08Scientific references＋
Peer-reviewed human research and formal evidence reviews. Open each source to inspect the complete paper record.
NAC and chronic bronchitis/COPD exacerbations
Dose context: ≤600 mg/day and >600 mg/day
Reduced exacerbations; the review proposed ≥1,200 mg/day for COPD with obstruction and 600 mg/day for chronic bronchitis without obstruction.
Oral NAC in chronic bronchitis
Dose context: <1,200 mg/day for ≥3 months
Reduced exacerbations and improved symptoms without a significant adverse-event increase.
NAC in chronic obstructive pulmonary disease
Dose context: Low-dose and high-dose oral protocols
NAC modestly reduced exacerbations, while ventilation, quality-of-life and glutathione outcomes did not show clear benefit.
09Expert & media references＋
Podcast and practitioner statements are clearly separated from research. They may explain practice or emerging ideas, but do not prove efficacy.
Dose Radar will leave this lane empty rather than invent or infer a professional opinion.